Abbvie Inc. vs Gilead Sciences Inc
ABBV vs GILD — side-by-side comparison from reported financials. ABBV leads 4, GILD leads 6 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Gilead Sciences Inc
GILD · Healthcare
$151.20+2.79%Mixed
| Metric | ABBV | GILD |
|---|---|---|
| Price | $276.43 | $151.20 |
| Market cap | $488B | $187B |
| Revenue (TTM) | $64.4B | $30.5B |
| Revenue growth | +1.8% | +2.6% |
| Net margin | 9.8% | -10.6% |
| Free cash flow | $18.2B | $12.9B |
| Net cash (debt) | ($56.2B) | ($24.9B) |
| 1-year price return | +19.8% | +29.5% |
| P/E | 77.4 | 22.0 |
| P/E vs own history (cheap-side %) | 23% | 78% |
| Dividend yield | 2.45% | 3.24% |
| Return on equity | 96% | -16% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 9 of 11 |
| Employees | 57,000 | 17,000 |
Full résumé-style profiles: ABBV CV · GILD CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.